Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.
Lead Product(s): Zofin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zofin
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Organicell Regenerative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 20, 2020